A Three lncRNA Set: AC009975.1, POTEH-AS1 and AL390243.1 as Nodal Efficacy Biomarker of Neoadjuvant Therapy for HER-2 Positive Breast Cancer
PurposeThe study aimed to explore whether the expression of lncRNAs in primary tumors could predict nodal efficacy after neoadjuvant therapy (NAT) for HER2+ breast cancer.MethodsTotal RNA was extracted from HER2+ breast cancer tissues before NAT (n=103) and from 48 pairs of cancers and para-cancers...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.779140/full |
| _version_ | 1818404128564445184 |
|---|---|
| author | Zhao Bi Peng-Fei Qiu Yue Zhang Xing-Guo Song Peng Chen Li Xie Yong-Sheng Wang Xian-Rang Song |
| author_facet | Zhao Bi Peng-Fei Qiu Yue Zhang Xing-Guo Song Peng Chen Li Xie Yong-Sheng Wang Xian-Rang Song |
| author_sort | Zhao Bi |
| collection | DOAJ |
| description | PurposeThe study aimed to explore whether the expression of lncRNAs in primary tumors could predict nodal efficacy after neoadjuvant therapy (NAT) for HER2+ breast cancer.MethodsTotal RNA was extracted from HER2+ breast cancer tissues before NAT (n=103) and from 48 pairs of cancers and para-cancers tissues that did not receive NAT. Different lncRNAs were selected by microarray, validated by qPCR, and analyzed to illuminate their potential as nodal efficacy biomarkers after NAT.ResultsOur results demonstrated that three lncRNA sets, lncRNA-AL390243.1, POTEH-AS1, and lncRNA-AC009975.1, were up-regulated in non-apCR tissues. The AUC value was 0.789 (95%CI: 0.703-0.876). The multivariate logistic regression analysis identified the expression of lncRNA-AL390243.1 (OR 5.143; 95% CI: 1.570-16.847), tumor type (OR 0.144; 95% CI: 0.024-0.855), and nodal stage (OR 0.507; 95% CI: 0.289-0.888) as independent predictors for apCR after NAT in HER2+ patients (all p<0.05). Then the three predictors were used to create a predictive nomogram. The AUC value was 0.859 (95%CI: 0.790-0.929). The calibration curve showed a satisfactory fit between predictive and actual observation based on internal validation with a bootstrap resampling frequency of 1000. Patients with higher expression of lncRNA-AL390243.1 had worse survival. LncRNA-AL390243.1 was up-regulated more in the nodal positive subgroup than in the nodal negative subgroup (p=0.0271).ConclusionThe lncRNA-AL390243.1, POTEH-AS1, and lncRNA-AC009975.1 were upregulated in non-apCR breast cancer tissues. These three lncRNAs might have the potential to be used as predictive biomarkers of nodal efficacy of HER2+ breast cancer. Further studies are required to illuminate the underlying molecular mechanisms further. |
| first_indexed | 2024-12-14T08:35:14Z |
| format | Article |
| id | doaj.art-53d85b73a3af4fffbba56f968f21c35f |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-14T08:35:14Z |
| publishDate | 2021-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-53d85b73a3af4fffbba56f968f21c35f2022-12-21T23:09:25ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-12-011110.3389/fonc.2021.779140779140A Three lncRNA Set: AC009975.1, POTEH-AS1 and AL390243.1 as Nodal Efficacy Biomarker of Neoadjuvant Therapy for HER-2 Positive Breast CancerZhao BiPeng-Fei QiuYue ZhangXing-Guo SongPeng ChenLi XieYong-Sheng WangXian-Rang SongPurposeThe study aimed to explore whether the expression of lncRNAs in primary tumors could predict nodal efficacy after neoadjuvant therapy (NAT) for HER2+ breast cancer.MethodsTotal RNA was extracted from HER2+ breast cancer tissues before NAT (n=103) and from 48 pairs of cancers and para-cancers tissues that did not receive NAT. Different lncRNAs were selected by microarray, validated by qPCR, and analyzed to illuminate their potential as nodal efficacy biomarkers after NAT.ResultsOur results demonstrated that three lncRNA sets, lncRNA-AL390243.1, POTEH-AS1, and lncRNA-AC009975.1, were up-regulated in non-apCR tissues. The AUC value was 0.789 (95%CI: 0.703-0.876). The multivariate logistic regression analysis identified the expression of lncRNA-AL390243.1 (OR 5.143; 95% CI: 1.570-16.847), tumor type (OR 0.144; 95% CI: 0.024-0.855), and nodal stage (OR 0.507; 95% CI: 0.289-0.888) as independent predictors for apCR after NAT in HER2+ patients (all p<0.05). Then the three predictors were used to create a predictive nomogram. The AUC value was 0.859 (95%CI: 0.790-0.929). The calibration curve showed a satisfactory fit between predictive and actual observation based on internal validation with a bootstrap resampling frequency of 1000. Patients with higher expression of lncRNA-AL390243.1 had worse survival. LncRNA-AL390243.1 was up-regulated more in the nodal positive subgroup than in the nodal negative subgroup (p=0.0271).ConclusionThe lncRNA-AL390243.1, POTEH-AS1, and lncRNA-AC009975.1 were upregulated in non-apCR breast cancer tissues. These three lncRNAs might have the potential to be used as predictive biomarkers of nodal efficacy of HER2+ breast cancer. Further studies are required to illuminate the underlying molecular mechanisms further.https://www.frontiersin.org/articles/10.3389/fonc.2021.779140/fullbreast cancerneoadjuvant therapyHER-2LncRNA-AC009975.1POTEH-AS1lncRNA-AL390243.1 |
| spellingShingle | Zhao Bi Peng-Fei Qiu Yue Zhang Xing-Guo Song Peng Chen Li Xie Yong-Sheng Wang Xian-Rang Song A Three lncRNA Set: AC009975.1, POTEH-AS1 and AL390243.1 as Nodal Efficacy Biomarker of Neoadjuvant Therapy for HER-2 Positive Breast Cancer Frontiers in Oncology breast cancer neoadjuvant therapy HER-2 LncRNA-AC009975.1 POTEH-AS1 lncRNA-AL390243.1 |
| title | A Three lncRNA Set: AC009975.1, POTEH-AS1 and AL390243.1 as Nodal Efficacy Biomarker of Neoadjuvant Therapy for HER-2 Positive Breast Cancer |
| title_full | A Three lncRNA Set: AC009975.1, POTEH-AS1 and AL390243.1 as Nodal Efficacy Biomarker of Neoadjuvant Therapy for HER-2 Positive Breast Cancer |
| title_fullStr | A Three lncRNA Set: AC009975.1, POTEH-AS1 and AL390243.1 as Nodal Efficacy Biomarker of Neoadjuvant Therapy for HER-2 Positive Breast Cancer |
| title_full_unstemmed | A Three lncRNA Set: AC009975.1, POTEH-AS1 and AL390243.1 as Nodal Efficacy Biomarker of Neoadjuvant Therapy for HER-2 Positive Breast Cancer |
| title_short | A Three lncRNA Set: AC009975.1, POTEH-AS1 and AL390243.1 as Nodal Efficacy Biomarker of Neoadjuvant Therapy for HER-2 Positive Breast Cancer |
| title_sort | three lncrna set ac009975 1 poteh as1 and al390243 1 as nodal efficacy biomarker of neoadjuvant therapy for her 2 positive breast cancer |
| topic | breast cancer neoadjuvant therapy HER-2 LncRNA-AC009975.1 POTEH-AS1 lncRNA-AL390243.1 |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.779140/full |
| work_keys_str_mv | AT zhaobi athreelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer AT pengfeiqiu athreelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer AT yuezhang athreelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer AT xingguosong athreelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer AT pengchen athreelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer AT lixie athreelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer AT yongshengwang athreelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer AT xianrangsong athreelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer AT zhaobi threelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer AT pengfeiqiu threelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer AT yuezhang threelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer AT xingguosong threelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer AT pengchen threelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer AT lixie threelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer AT yongshengwang threelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer AT xianrangsong threelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer |